If there is anything that is worth reporting it must be NuVasive. How does this company continue to razzle and dazzle the track? Could this company be running on today's odds for Stately Victor? Could it be because of the jockey riding this horse, Alex Lukianov? Considering that this company is truly a one-trick pony platform, XLIF and NeuroVision how do they continue to win every quarter? Eventually, all thoroughbreds are put out to stud. Spare us the Osteocel story because Devil May Care is running at 11-1 odds to win. Is it consulting agreements? Mission Impossible 20-1. Is it a sophisticated educational platform? Ice Box is running at 9-1. Is it the wining and dining? Pick Super Saver at 8-1. Let's face it, NuVasive is beating Synthes, Medtronic and DePuy at their own game. But why? One has to wonder how long they will ride this horse? As long as that three-tiered training program for XLIF exists, they've got the surgeons by their hearts and minds, and you don't even need the kool-aid. But our readers must admit, it gets entertaining when a new CFO is now an expert on XLIF and spine surgery because he works for NuVasive.
So in closing, TSB is standing near "Lookin at Lucky," and I'm feeling pretty lucky. So I'll be ordering another mint julep and thinking about those not fortunate enough to take in this event. TSB wants to know what our readers think?